Orchestrated and dynamic nucleotide addition cycle during respiratory syncytial virus early-stage elongation.
Summary
High-resolution cryo-EM captures RSV polymerase across four nucleotide addition cycle states, revealing large-scale domain rearrangements and micro-motif interactions that coordinate catalysis. These structural insights identify conserved interaction networks as potential antiviral targets against RSV and related mononegavirales.
Key Findings
- Captured four discrete NAC states (NTP-bound, pre-reaction, pre-translocation, post-translocation) of the RSV L:P polymerase during early elongation.
- Observed all five L domains in NTP-bound and post-translocation states, versus only two domains in pre-reaction and pre-translocation.
- Revealed dynamic interaction networks among catalytic residues/motifs, RNA template/product, incoming NTP, and metal ions across states.
- Provides structural basis to target conserved motifs and interfaces for antiviral drug design.
Clinical Implications
Although preclinical, the defined NAC-state interaction hotspots can guide small-molecule or nucleotide analog inhibitor development, with potential translation to broad antivirals against RSV and other nonsegmented negative-sense RNA viruses.
Why It Matters
This is the first comprehensive visualization of RSV polymerase through early elongation NAC states, enabling rational, structure-guided inhibitor design against a leading pediatric pathogen.
Limitations
- In vitro structural snapshots without in vivo validation.
- Drug inhibition or resistance mutations were not experimentally tested in this study.
Future Directions
Integrate structure-guided medicinal chemistry to target NAC-state interfaces; validate inhibitory mechanisms in cell and animal models; assess conservation of targetable motifs across mononegavirales for pan-family antivirals.
Study Information
- Study Type
- Basic mechanistic study
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical structural biology study elucidating molecular mechanism without clinical outcomes.
- Study Design
- OTHER